Episodic Ataxia Type 6 C2675211
A genetic condition causing episodic ataxia that may be associated with migraine-like symptoms. Onset typically occurs in childhood or early adulthood. Treatment addresses symptom management and may include preventive approaches.
Key facts at a glance
- ICD-10
- G43.909
- ICD-11
- 8A00.0
- Body system
- neurologic
- Severity
- moderate
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Ataxia
(neurologic)Generalized symptoms
(neurologic)Noticeable symptoms that may vary in intensity over time.
Frequency: Common at all stages
Balance problems
(neurologic)Nystagmus
(neurologic)Headache
(neurologic)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Acetazolamide therapy
Carbonic anhydrase inhibitor considered first-line for reducing frequency and severity of episodic ataxia attacks in type 6, particularly effective in patients with CACNA1A mutations.
Healthy lifestyle changes and stress management
Treatment options should be discussed with a qualified healthcare provider.
Stress management and trigger avoidance
Comprehensive stress reduction techniques including relaxation training, meditation, and identification of personal episode triggers like intense exercise or emotional stress.
Additional treatment options
Coordination and balance training
Targeted physical therapy focusing on balance exercises, gait training, and coordination activities to maintain motor function and reduce fall risk during episodes.
physical_therapy4-Aminopyridine supplementation
Potassium channel blocker that may provide symptom relief for patients with inadequate response to acetazolamide monotherapy.
medicationSerial neurological evaluations
Regular neurological assessments to monitor for progression to permanent cerebellar ataxia and adjust treatment protocols accordingly.
monitoringWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Episodic Ataxia Type 6 C2675211?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Jen JC, Graves TD, Griggs RC. Practice guideline: Treatment of episodic ataxias. American Academy of Neurology. 2021.
Kullmann DM, Waxman SG. Channelopathies and episodic neurological symptoms: A clinical review. Nat Rev Neurol. 2022.
Hamsanan MN, Manjaly M, Bhattacharya K. Expanding phenotype of SLC1A3-related episodic ataxia type 6. Mov Disord Clin Pract. 2023.
Spooner JR, Baloh RW, Jen JC. Genetic ataxias and channelopathies: Molecular classification and clinical implications. Ann Neurol. 2020.
Medication Comparisons
Compare medications used to treat Episodic Ataxia Type 6 C2675211. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy